Corvus Pharmaceuticals (CRVS) director granted 30,000 stock options at $16.02

Rhea-AI Filing Summary

Corvus Pharmaceuticals director Andrew C. Chan received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $16.02 per share and expire on April 23, 2036. All 30,000 options were reported as directly owned following the grant.

The footnote explains that these options vest in three equal annual installments. One-third of the shares subject to the option will vest on each annual anniversary starting April 23, 2026, as long as Chan continues his service relationship with Corvus on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chan Andrew C.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 30,000 options Exercise price: $16.02 per share Expiration date: April 23, 2036 +2 more

5 metrics

Options granted 30,000 options Stock Option (Right to Buy) covering common stock

Exercise price $16.02 per share Stock option grant to Andrew C. Chan

Expiration date April 23, 2036 Option term for 30,000-share grant

Post-grant derivative holdings 30,000 options Total options following transaction

Vesting schedule start April 23, 2026 First anniversary for 1/3 vesting

Key Terms

Stock Option (Right to Buy), exercise price, vest, annual anniversary, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "16.0200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The underlying shares subject to the option vest and become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual anniversary financial

"on each annual anniversary measured from April 23, 2026"

continued service relationship financial

"subject to Reporting Person's continued service relationship with the Issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Andrew C.

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.02	04/23/2026		A		30,000		(1)	04/23/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 23, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

	/s/ Leiv Lea, as Attorney-in-Fact for Andrew C. Chan	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Andrew C. Chan acquire in this Form 4 for Corvus Pharmaceuticals (CRVS)?

Andrew C. Chan was granted stock options covering 30,000 shares of Corvus Pharmaceuticals common stock. These options give him the right to buy shares at a fixed exercise price of $16.02 per share before they expire on April 23, 2036.

What is the exercise price and expiration date of Andrew C. Chan’s CRVS stock options?

The granted stock options have an exercise price of $16.02 per share and expire on April 23, 2036. This means Chan can choose to buy up to 30,000 shares at $16.02 any time before that expiration date, once vested.

How do the 30,000 Corvus Pharmaceuticals (CRVS) options granted to Andrew C. Chan vest?

The 30,000 options vest in three equal annual installments beginning April 23, 2026. One-third of the options vest on each yearly anniversary from that date, provided Chan maintains a continued service relationship with Corvus Pharmaceuticals on each vesting date.

How many Corvus Pharmaceuticals (CRVS) derivative securities does Andrew C. Chan hold after this grant?

Following this grant, Andrew C. Chan is reported as directly holding stock options over 30,000 shares of Corvus Pharmaceuticals common stock. This filing only shows this single grant and does not list any additional remaining derivative positions in the derivative summary.

Is Andrew C. Chan’s Form 4 transaction in CRVS an open-market buy or a compensation grant?

The Form 4 describes the transaction as a grant or award acquisition of stock options, coded as “A.” This indicates a compensation-related stock option grant rather than an open-market purchase, with 30,000 options awarded at a $16.02 exercise price.